Trial | NCT00879138  Report issue

Title

Efficacy and Safety of VA106483 in Elderly Males
A Double-blind, Placebo-controlled Dose Response Study to Investigate Pharmacodynamics and Pharmacokinetics of Single and Repeated Oral Doses of VA106483 in Elderly Male Subjects

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    fedovapagon ...

  • Study Participants

    27
A double blind, placebo-controlled, dose ranging study in males over the age of 65, who have a history of nocturia. The study will investigate pharmacodynamic outcomes (urine volumes and osmolality, circulating coagulation factors and haemodynamics) and pharmacokinetics, of both single and multiple oral doses of VA106483 at three dose levels, under conditions of controlled hydration.
VA106483 is a selective vasopressin V2 receptor agonist which is currently under development for the treatment of nocturia in males. This study examines the pharmacological action of VA106483 on markers of clinical efficacy (urine volumes and osmolality) and safety markers (coagulation factors and haemodynamics). The study will also assess the pharmacokinetics in the study population. The study design includes both cross-over and parallel phases so that pharmacodynamic and pharmacokinetic parameters can be assessed following both single and repeat dosing. Three dose levels will be given.
Study Started
Aug 31
2008
Primary Completion
Feb 28
2009
Study Completion
Mar 31
2009
Last Update
Oct 31
2018

Drug Sugar pill

Drug VA106483

Sugar pill Placebo Comparator

VA106483 2 mg Experimental

VA106483 4 mg Experimental

VA106483 8 mg Experimental

Criteria 

Inclusion Criteria:

Males 65 years and above with history of nocturia

Exclusion Criteria:

Any clinically significant concomitant medical disease, condition or abnormal laboratory test result
Participation in any other clinical study within 30 days
Intake of non-prescription medication within 14 days
No Results Posted